carmustine has been researched along with Invasiveness, Neoplasm in 13 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| " Two doses of carmustine at intervals of one week could eradicate the disease even during the phase of logarithmic growth of the leukaemic cells, this result depending upon the level of treatment and time of dosing post-inoculation with leukaemic cells." | 1.27 | Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia. ( Bock, M; Jackson, H; Jackson, NC; Lendon, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, C | 1 |
| Rao, R | 1 |
| Cai, Z | 1 |
| Yang, H | 1 |
| Zhang, L | 1 |
| Ji, S | 1 |
| Zhang, C | 1 |
| Gao, D | 1 |
| Hu, Y | 1 |
| Li, J | 1 |
| Xiong, W | 1 |
| Jiang, H | 1 |
| Chu, J | 1 |
| Wu, D | 1 |
| McCormack, A | 1 |
| Dekkers, OM | 1 |
| Petersenn, S | 1 |
| Popovic, V | 1 |
| Trouillas, J | 1 |
| Raverot, G | 1 |
| Burman, P | 1 |
| Ciochetto, C | 1 |
| Botto, B | 1 |
| Passera, R | 1 |
| Bellò, M | 1 |
| Benevolo, G | 1 |
| Boccomini, C | 1 |
| Castellino, A | 1 |
| Chiappella, A | 1 |
| Freilone, R | 1 |
| Nicolosi, M | 1 |
| Orsucci, L | 1 |
| Pecoraro, C | 1 |
| Pregno, P | 1 |
| Bisi, G | 1 |
| Vitolo, U | 1 |
| Yan, YR | 1 |
| Xie, Q | 1 |
| Li, F | 1 |
| Zhang, Y | 1 |
| Ma, JW | 1 |
| Xie, SM | 1 |
| Li, HY | 1 |
| Zhong, XY | 1 |
| Hudish, TM | 1 |
| Opincariu, LI | 1 |
| Mozer, AB | 1 |
| Johnson, MS | 1 |
| Cleaver, TG | 1 |
| Malkoski, SP | 1 |
| Merrick, DT | 1 |
| Keith, RL | 1 |
| Saito, R | 1 |
| Bringas, J | 1 |
| Mirek, H | 1 |
| Berger, MS | 1 |
| Bankiewicz, KS | 1 |
| Jackson, H | 1 |
| Jackson, NC | 1 |
| Bock, M | 1 |
| Lendon, M | 1 |
| Kakeji, Y | 1 |
| Teicher, BA | 1 |
| Go, Y | 1 |
| Chintala, SK | 1 |
| Rayford, A | 1 |
| Gagercas, E | 1 |
| Ali-Osman, F | 1 |
| Venkaiah, B | 1 |
| Sawaya, R | 1 |
| Gokaslan, Z | 1 |
| Nicolson, GL | 1 |
| Rao, JS | 1 |
| Bauman, GS | 1 |
| MacDonald, W | 1 |
| Moore, E | 1 |
| Ramsey, DA | 1 |
| Fisher, BJ | 1 |
| Amberger, VR | 1 |
| Del Maestro, RM | 1 |
| Alvarnas, JC | 1 |
| Negrin, RS | 1 |
| Horning, SJ | 1 |
| Hu, WW | 1 |
| Long, GD | 1 |
| Schriber, JR | 1 |
| Stockerl-Goldstein, K | 1 |
| Tierney, K | 1 |
| Wong, R | 1 |
| Blume, KG | 1 |
| Chao, NJ | 1 |
| Godard, J | 1 |
| Viennet, G | 1 |
| Raul, JS | 1 |
| Plouvier, E | 1 |
| Miny, J | 1 |
| Jacquet, G | 1 |
| Czorny, A | 1 |
| Abernathey, CD | 1 |
| Kooistra, KL | 1 |
| Wilcox, GL | 1 |
| Laws, ER | 1 |
1 trial available for carmustine and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Car | 2018 |
12 other studies available for carmustine and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Microclaw Array Fabricated by Single Exposure of Femtosecond Airy Beam and Self-Assembly for Regulating Cell Migratory Plasticity.
Topics: Breast Neoplasms; Carmustine; Cell Line, Tumor; Cell Movement; Epithelial Cells; Female; Humans; MCF | 2023 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice.
Topics: Administration, Topical; Animals; Bronchial Neoplasms; Carcinogens; Carcinoma, Squamous Cell; Carmus | 2012 |
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Culture Techniques; Ce | 2004 |
Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia.
Topics: Animals; Carmustine; Disease Models, Animal; Female; Leukemia, Lymphoid; Male; Meningeal Neoplasms; | 1984 |
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 1997 |
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cisplatin; Culture Media, Seru | 1997 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carm | 2000 |
[Intramedullary spread of a cerebral oligodendroglioma. Two case reports].
Topics: Abducens Nerve Diseases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2000 |
New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma; Hu | 1988 |